TRAW
NASDAQTraws Pharma Inc.
News25/Ratings1
News · 26 weeks44-11%
2025-10-262026-04-19
Mix2190d
- Insider11(52%)
- SEC Filings5(24%)
- Other3(14%)
- Offering1(5%)
- Earnings1(5%)
Latest news
25 items- SECSEC Form 10-K filed by Traws Pharma Inc.10-K - Traws Pharma, Inc. (0001130598) (Filer)
- SECTraws Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- PRTraws Pharma Reports Full Year 2025 Results and Provides Business HighlightsTivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity, Ratutrelvir topline Phase 2a data show a differentiated profile versus PAXLOVID® in COVID patients, with good overall safety; final study analysis underway Private financing of up to $60M (with $10M of such amount upfront) offering of common stock and milestone-based and three-year warrants completed on April 15, 2026 supporting operations into Q1 2027 Investor Update call today, April 15, 2026 at 4:30 PM ET NEWTOWN, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company
- PRTraws Pharma Announces Up to $60 Million Private Placement FinancingFinancing led by Sirenia Capital Management LP advances Traws Pharma's influenza program through a human challenge trial for tivoxavir marboxil in the United Kingdom NEWTOWN, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, "Traws Pharma", "Traws" or "the Company")), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that it has entered into a securities purchase agreement with new and existing institutional and accredited investors for a private investment in public equity ("PIPE") financing expected to provide approximately $10.0 million in gross proceed
- SECTraws Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- INSIDERSEC Form 4 filed by Parker Charles Nolan4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 3 filed by new insider Parker Charles Nolan3 - Traws Pharma, Inc. (0001130598) (Issuer)
- SECSEC Form NT 10-K filed by Traws Pharma Inc.NT 10-K - Traws Pharma, Inc. (0001130598) (Filer)
- INSIDERSEC Form 4 filed by Traws Pharma Inc.4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Traws Pharma Inc.4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Traws Pharma Inc.4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Director Cautreels Werner4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Traws Pharma Inc.4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Traws Pharma Inc.4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Traws Pharma Inc.4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Director Stover Jack E4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Director Shoemaker Mary Teresa4 - Traws Pharma, Inc. (0001130598) (Issuer)
- SECTraws Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- PRTraws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal InfluenzaCompleted clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID®-ineligible patients, representing a significant population with no effective treatment options Pre-clinical analysis of tivoxavir marboxil tablets demonstrated significantly increased exposure compared to a prototype formulation with predicted 28-day protection in humans from influenza infections against a wide range of seasonal and pandemic variants PK study of compressed tivoxavir marboxil tablets submitted under open IND in Australia and preparations are
- SECTraws Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- PRTraws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal InfluenzaOngoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated in PAXLOVID®-ineligible patients, representing a significant population with few effective treatment options Compressed tablets of tivoxavir marboxil predicted to provide 28-day protection from influenza against wide range of seasonal and pandemic-potential variants Human influenza prophylaxis challenge study time slot secured for June 2026 NEWTOWN, Pa., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical
- SECTraws Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- PRTraws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 PatientsIND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile Updated clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds and faster time to sustained symptom resolution Ratutrelvir's safety and efficacy advantage recapitulated in PAXLOVID®-ineligible patients, representing a significant population with few effective treatment options Full study enrollment expected in January 2026 NEWTOWN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pha
- SECTraws Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- PRTraws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 PatientsRatutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid®-ineligible patients, representing a significant population with few effective treatment options Final data analysis to be reported in January 2026 NEWTOWN, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that interim data with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, demonstrated a dif